Gyre Therapeutics, Inc. (GYRE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$6.95-3.07%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Gyre Therapeutics aims to grow revenue to about $105.75 million in 2026. The company is completing the Cullgen acquisition to boost its capabilities. Management is working to stabilize leadership after recent changes. These steps could help Gyre improve its business and reduce losses.
Gyre is still losing money and missed earnings recently. Revenue dropped sharply in early 2026 and the outlook remains uncertain. Legal issues and executive turnover add risks. The company may struggle to meet its revenue targets or turn profitable soon.
The stock price reflects about 8% revenue growth and is down roughly 57% from our valuation range. The market expects a slow recovery but remains cautious given recent earnings misses and losses. Our view aligns with this cautious outlook.
Breaks if: Acquisition fails to complete or integration stalls significantly
Breaks if: Additional key executive departures or leadership disruptions occur
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
GYRE is positioned as a speculative growth investment within the healthcare sector. The company is navigating through a volatile management phase while focusing on integrating a recent acquisition and advancing its clinical pipeline.
The current valuation suggests that GYRE is relatively cheap compared to its peers. The market appears to have low expectations, as indicated by a negative expectations gap.
Management is on track with its priorities, particularly in integrating Cullgen Inc. and affirming revenue guidance. However, there is an elevated risk of missing earnings in the near term, as the company has a history of consecutive misses.
The future performance of GYRE hinges on several factors, including the ability to maintain guidance and the outcomes of ongoing clinical trials. Additionally, the overall health of the job market and performance of sector bellwethers will be critical.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss has negatively impacted the outlook. This miss raises concerns about the company's performance and future guidance. The overall market backdrop has also shifted to a risk-off sentiment, adding further pressure.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Full year 2026 revenue falls below $100.5 million
In the next 1 to 3 years, GYRE's success will depend on effective management execution and external market conditions. Not investment advice.